
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is attractive because it has been refocused into a pure-play prostate cancer diagnostics business after discontinuing Resolve, removing the $10.4M Novitas liability, and strengthening financial flexibility with a pro forma cash balance of about $39M. Its growth thesis is supported by Q2'26 revenue of $27.2M, up 16% Y/Y and above estimates, plus reiterated 2026 revenue guidance of $110M-$115M, while the recent $15M Exosome Diagnostics acquisition adds a market-leading EPI test and is expected to contribute $20M+ of revenue in 2026. The company also benefits from secular tailwinds in a urology market expected to grow 5%-10%+, with ProtecT, GPS, and NCCN evidence potentially widening adoption and supporting a move toward positive Adj. EBITDA in Q4'26 and about 20% margin exiting 2028.
Bears say
MDxHealth is facing a deteriorating fundamental profile after pre-announcing Q3 revenue of $22.7M, down 5% year over year and 17% sequentially, while tissue volumes and liquid-based test volumes also missed expectations, signaling weaker commercial execution. The company’s decision to suspend its 2026 revenue guidance, despite less than one quarter remaining in the year, undermines confidence in visibility and suggests the Resolve UTI wind-down and unexpected sales rep turnover materially disrupted growth momentum. Balance sheet concerns further pressure the outlook, with only $31.7M of cash against remaining contingent payments of $18M in 2027 and $21M in 2028, alongside other liabilities and heightened reimbursement, competition, and pricing risks.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MDxHealth SA (MDXH) Forecast
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares